E Fund Management (HK)’s CG Oncology CGON Stock Holding History

E Fund Management (HK)’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.8K	Buy	+233	New	+$13.2K	0.01%	235

Other funds holding CGON

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

E Fund Management (HK)'s CGON Position: Q1 2026 in Review

E Fund Management (HK) opened a new position in CG Oncology (CGON) in Q1 2026: 233 shares worth $15.8K. The stake represents 0.01% of the portfolio and ranks #235 among its holdings.

233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

E Fund Management (HK) held 233 shares of CG Oncology worth $15.8K as of Q1 2026.
CG Oncology was a new E Fund Management (HK) position in Q1 2026.
CG Oncology made up 0.01% of E Fund Management (HK)'s portfolio in Q1 2026, its #235 holding.
233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on E Fund Management (HK)'s 13F filing for Q1 2026, filed 8 Apr 2026.